Formulary conversion programs: the need for patient-specific risk assessment

MedGenMed. 2004 Sep 14;6(3):28.

Authors

Sonal Singh¹, Rakesh Shrivastava, Vijay Das

Affiliation

¹ Department of Internal Medicine, Unity Health System, Rochester, New York, USA.

PMID: 15520652
PMCID: PMC1435601

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Atorvastatin
Cyclosporine / adverse effects
Drug Interactions
Female
Formularies as Topic*
Heart Transplantation*
Heptanoic Acids / therapeutic use*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Immunosuppressive Agents / adverse effects
Postoperative Care
Pyrroles / therapeutic use*
Rhabdomyolysis / chemically induced*
Risk Assessment
Simvastatin / adverse effects*

Substances

Heptanoic Acids
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immunosuppressive Agents
Pyrroles
Cyclosporine
Atorvastatin
Simvastatin